Table 2.

LPD directed therapy at time of COVID-19 diagnosis.

Anti-CD20 ± combination	60	16.4%
Obinutuzumab	58	15.8%
Ofatumumab	1	0.3%
Obinutuzumab + Lenalidomide	1	0.3%
Anti-CD30 ± combination	16	4.4%
Brentuximab	15	4.1%
Brentuximab + Nivolumab	1	0.3%
Anti-CD79	5	1.4%
Polatuzumab	5	1.4%
Anti-PD1	3	0.8%
Nivolumab	1	0.3%
Pembrolizumab	2	0.5%
BCL2 ± combination	33	9.0%
Venetoclax	27	7.4%
Obinutuzumab + Venetoclax	6	1.6%
IMiDs	28	7.7%
Lenalidomide	28	7.7%
BTKs ± combination	201	54.9%
Ibrutinib	172	47.0%
Acalabrutinib	6	1.6%
Zanabrutinib	8	2.2%
Ibrutinib + Obinutuzumab	1	0.3%
Ibrutinib + Venetoclax	9	2.5%
Ibrutinib + Acalabrutinib	1	0.3%
Idelalisib + Acalabrutinib	1	0.3%
Obinutuzumab + Zanabrutinib	1	0.3%
Venetoclax + Acalabrutinib	2	0.5%
PI3K inhibitor	17	4.6%
Idelalisib	17	4.6%
Other treatment combinations	3	0.8%
Ibrutinib + Obinutuzumab + Venetoclax	1	0.3%
Ibrutinib + Idelalisib + Venetoclax	1	0.3%
Obinutuzumab + Venetoclax + Acalabrutinib	1	0.3%